Moderate

Haemophilia - chronic management & prophylaxis

haemophilia mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

X-linked deficiency of factor VIII (A) or IX (B) causing recurrent joint and soft-tissue bleeding. Modern care centres on prophylaxis to prevent arthropathy using factor concentrates, extended-half-life products, or non-factor agents such as emicizumab.

Red flags

  • Head injury or suspected intracranial bleed (treat before imaging)
  • Rising inhibitor titre with failure to respond to factor
  • Compartment syndrome from muscle bleed
  • Throat/neck or retroperitoneal bleeding
  • Acute haemarthrosis with fixed joint

Assessment

Differential diagnosis

  • Von Willebrand disease
  • Acquired haemophilia
  • Other factor deficiencies
  • Platelet disorder
  • Vitamin K deficiency

Investigations

  • Coagulation screen (prolonged APTT, normal PT)
  • Factor VIII or IX assay to grade severity
  • Inhibitor assay (Bethesda) regularly and before surgery
  • Genetic testing for carrier/prenatal counselling
  • Joint imaging (MRI/ultrasound) for arthropathy
  • Viral screen (historic blood-product exposure)

Management

  • Confirm diagnosis, factor type and severity (severe <1%, moderate 1-5%, mild >5-40%)
  • Enrol in a comprehensive haemophilia centre with multidisciplinary care
  • Offer prophylaxis for severe disease to keep factor levels above the bleeding threshold and prevent arthropathy
  • Choose regimen: standard or extended-half-life factor concentrate, or emicizumab (FVIII mimetic) for haemophilia A with or without inhibitors
  • Teach home treatment and rapid factor replacement for breakthrough bleeds
  • Monitor for inhibitor development, especially early in treatment
  • Manage inhibitors with bypassing agents and immune tolerance induction
  • Provide physiotherapy, joint protection and manage established arthropathy
  • Avoid intramuscular injections, NSAIDs and antiplatelets; vaccinate subcutaneously
  • Consider gene therapy in eligible adults and give genetic counselling

Drugs & doses

Recombinant factor VIII prophylaxis 20-40 IU/kg IV 2-3 times/week (haemophilia A)
Recombinant factor IX prophylaxis 40-60 IU/kg IV 1-2 times/week (haemophilia B)
Emicizumab load 3 mg/kg SC weekly x4 then 1.5 mg/kg weekly (or 3 mg/kg q2wk / 6 mg/kg q4wk)
Tranexamic acid 1 g PO/IV three times daily for mucosal bleeding (avoid with aPCC)

Disposition

Comprehensive haemophilia centre; home therapy with 24-hour access; admit for major or CNS bleeds.

Complications & pitfalls

  • Chronic haemophilic arthropathy
  • Inhibitor development
  • Intracranial haemorrhage
  • Transfusion-transmitted infection (historic)
  • Thrombotic risk if emicizumab combined with high-dose aPCC

Exam pearls

  • Treat a suspected head bleed with factor immediately, before imaging
  • Emicizumab transforms care but renders APTT-based monitoring and aPCC dosing hazardous
  • Early prophylaxis prevents the disabling arthropathy of severe disease
  • Never give IM injections or NSAIDs
  • Inhibitors are the biggest modern treatment challenge - monitor Bethesda titres

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.